Ralph D. Sanderson

13.5k citations

128 papers · 11.1k indexed · 1 hit paper · h-index 64

Molecular Biology top 0.5%
Cell Biology top 0.05%
Hematology top 0.2%
Cancer Research top 0.5%
Oncology top 1%

Co-authors: Israël Vlodavsky Merton Bernfield Renato V. Iozzo Anurag Purushothaman Yang Yang Vishnu C. Ramani Neta Ilan Paul A. Lalor
Topics: Proteoglycans and glycosaminoglycans research (101 papers)Glycosylation and Glycoproteins Research (54 papers)Multiple Myeloma Research and Treatments (44 papers)
Cited by: Cell Biology Immunology and Allergy Hematology
Journals: Chemical Reviews Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States Israel Italy

In The Last Decade

Ralph D. Sanderson

127 papers receiving 11.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

2002 507 citations Fenghuang Zhan, Ralph D. Sanderson et al. Blood profile →

Peers

Countries citing papers authored by Ralph D. Sanderson

Since Specialization

Citations

This map shows the geographic impact of Ralph D. Sanderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph D. Sanderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph D. Sanderson more than expected).

Fields of papers citing papers by Ralph D. Sanderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph D. Sanderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph D. Sanderson. The network helps show where Ralph D. Sanderson may publish in the future.

Co-authorship network of co-authors of Ralph D. Sanderson

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph D. Sanderson. A scholar is included among the top collaborators of Ralph D. Sanderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph D. Sanderson. Ralph D. Sanderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nuclear localization of heparanase 2 (Hpa2) attenuates breast carcinoma growth and metastasis 2024 ·Cell Death and Disease ·(unknown),(unknown),Inna Naroditsky,Sari Feld,(unknown),Ilanit Boyango,(unknown),Olga Vornicova,(unknown),Preeti Singh,Gil Bar‐Sela,Hadassah Goldberg,Martin Götte,Andrew D. Sharrocks,Yaoyong Li,Ralph D. Sanderson,Neta Ilan,Israël Vlodavsky	4
2	Heparanase—A single protein with multiple enzymatic and nonenzymatic functions 2023 ·PubMed ·Israël Vlodavsky,(unknown),(unknown),(unknown),Ralph D. Sanderson,Neta Ilan	21
3	Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma 2023 ·Cells ·Olga Ostrovsky,Katia Beider,Hila Magen,Merav Leiba,Ralph D. Sanderson,Israël Vlodavsky,Arnon Nagler	2
4	Glycocalyx heparan sulfate cleavage promotes endothelial cell angiopoietin-2 expression by impairing shear stress–related AMPK/FoxO1 signaling 2022 ·JCI Insight ·Robert P. Richter,(unknown),Lei Zheng,Daniëlle Pretorius,Kaushlendra Tripathi,Ralph D. Sanderson,Amit Gaggar,Jillian R. Richter	20
5	Significance of host heparanase in promoting tumor growth and metastasis 2020 ·Matrix Biology ·(unknown),Lilach Gutter-Kapon,Neta Ilan,Tahira Batool,K. N. Singh,Andreas Digre,(unknown),Stellan Sandler,Yuval Shaked,Ralph D. Sanderson,Xiaomin Wang,Jin‐Ping Li,Israël Vlodavsky	24
6	Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth 2019 ·Cancer Research ·Udayan Bhattacharya,Lilach Gutter-Kapon,(unknown),Ilanit Boyango,Uri Barash,Shiming Yang,Jingjing Liu,(unknown),Ralph D. Sanderson,Yuval Shaked,Neta Ilan,Israël Vlodavsky	38
7	Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth 2016 ·Cancer Research ·DeannaLee M. Beauvais,Oisun Jung,Yang Yang,Ralph D. Sanderson,Alan C. Rapraeger	57
8	Heparanase Regulates Secretion, Composition, and Function of Tumor Cell-derived Exosomes 2013 ·Journal of Biological Chemistry ·(unknown),Anurag Purushothaman,Vishnu C. Ramani,Israël Vlodavsky,Ralph D. Sanderson	282
9	SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis 2011 ·Clinical Cancer Research ·(unknown),Vishnu C. Ramani,Yongsheng Ren,Annamaria Naggi,Giangiacomo Torri,Benito Casu,Sergio Penco,Claudio Pisano,Paolo Carminati,Monica Tortoreto,Franco Zunino,Israël Vlodavsky,Ralph D. Sanderson,Yang Yang	209
10	Heparanase Enhances Local and Systemic Osteolysis in Multiple Myeloma by Upregulating the Expression and Secretion of RANKL 2010 ·Cancer Research ·Yang Yang,Yongsheng Ren,Vishnu C. Ramani,Li Nan,Larry J. Suva,Ralph D. Sanderson	56
11	HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo 2005 ·Journal of Biological Chemistry ·Yuemeng Dai,Yang Yang,Veronica MacLeod,Xinping Yue,Alan C. Rapraeger,Zachary Shriver,Ganesh Venkataraman,Ram Sasisekharan,Ralph D. Sanderson	122
12	Heparanase Degrades Syndecan-1 and Perlecan Heparan Sulfate 2004 ·Journal of Biological Chemistry ·Jane Reiland,Ralph D. Sanderson,(unknown),Steven A. Barker,(unknown),Daniel D. Carson,Philippe Marchetti	115
13	Identification of an Invasion Regulatory Domain within the Core Protein of Syndecan-1 2004 ·Journal of Biological Chemistry ·J. Kevin Langford,Yang Yang,Thomas Kieber‐Emmons,Ralph D. Sanderson	41
14	High heparanase activity in multiple myeloma is associated with elevated microvessel density. 2003 ·PubMed ·Thomas J. Kelly,Hua‐Quan Miao,Yang Yang,Elizabeth Navarro,Paul Kussie,Yan Huang,Veronica MacLeod,(unknown),Lija Joseph,Fenghuang Zhan,Maurizio Zangari,Bart Barlogie,John D. Shaughnessy,Ralph D. Sanderson	146
15	Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate–mediated cell-cell adhesion 2001 ·Blood ·(unknown),Ralph D. Sanderson	47
16	Syndecan-1 Expression Is Decreased With Increasing Aggressiveness of Basal Cell Carcinoma 2000 ·American Journal of Dermatopathology ·Ilene B. Bayer‐Garner,(unknown),Ralph D. Sanderson,Bruce R. Smoller	35
17	ABSTRACTS SUBMITTED FOR THE 24TH MEETING OF THE SOCIETY FOR GLYCOBIOLOGY 1996 ·Glycobiology ·(unknown),(unknown),Laura L. Kiessling,Karen Colley,(unknown),(unknown),Ralph D. Sanderson,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	1
18	Syndecans as Anti-invasive Molecules on the Surface of Tumor Cells. 1995 ·Trends in Glycoscience and Glycotechnology ·Ralph D. Sanderson,(unknown)	1
19	Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. 1994 ·Journal of Biological Chemistry ·Ralph D. Sanderson,Jeremy E. Turnbull,J T Gallagher,Arthur D. Lander	145
20	Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors 1990 ·Philosophical transactions of the Royal Society of London. Series B, Biological sciences ·Merton Bernfield,Ralph D. Sanderson	178

About Ralph D. Sanderson

Ralph D. Sanderson is a scholar working on Cell Biology, Hematology and Immunology and Allergy, having authored 128 papers that have together received 11.1k indexed citations. Recurring topics across this work include Proteoglycans and glycosaminoglycans research (101 papers), Glycosylation and Glycoproteins Research (54 papers) and Multiple Myeloma Research and Treatments (44 papers). The work is most often cited by research in Cell Biology (6.0k citations), Immunology and Allergy (1.5k citations) and Hematology (2.1k citations). Ralph D. Sanderson has collaborated with scholars based in United States, Israel and Italy. Frequent co-authors include Israël Vlodavsky, Merton Bernfield, Renato V. Iozzo, Anurag Purushothaman, Yang Yang, Vishnu C. Ramani, Neta Ilan, Paul A. Lalor, Thomas J. Kelly and Shyam Bandari. Their work appears in journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact